Amgen Inc.’s (AMGN) and AstraZeneca’s (AZN) Tezspire Receives Positive Recommendation from the EU Medicines Agency

​Amgen Inc. (NASDAQ:AMGN) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Amgen Inc.’s (NASDAQ:AMGN) and AstraZeneca’s Tezspire received a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use.

​The approval is for treating adults with chronic rhinosinusitis with nasal polyps in the European Union. The recommendation is based on the results from the Phase III WAYPOINT trial, which showed that Tezspire significantly reduced nasal polyp size and nasal congestion compared to placebo after one year. Moreover, patients experienced a nasal polyp score reduction of -2.08 and a nasal congestion score drop of -1.04, both statistically significant.

​Notably, Tezspire helped nearly eliminate the need for surgery and greatly reduced systemic corticosteroid use by 89%. These findings address key challenges for CRSwNP patients who often suffer from repeated surgeries and long-term steroid side effects.

​Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures medicines for serious diseases.

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.